Ven­tyx Bio­sciences' stock drops over 70% af­ter ax­ing pso­ri­a­sis drug pro­gram

Ven­tyx Bio­sciences has axed the de­vel­op­ment of its ex­per­i­men­tal pso­ri­a­sis drug af­ter lack­lus­ter Phase II re­sults, send­ing its stock plum­met­ing about 73% to $3.75 in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER